Lipigon Pharmaceuticals AB (DE:9RP)
FRANKFURT:9RP
9RP Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EST
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.00 - €0.02
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€323.21K
Enterprise Value-€6.70M
Total Cash (Recent Filing)€10.21M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta65.81
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding605,933,700
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.44
Price to Sales (P/S)0.00
P/FCF Ratio-0.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Cardiometabolic Therapeutic NicheA clear strategic focus on cardiometabolic diseases concentrates R&D resources on a large, persistent clinical need. This specialization supports deeper domain expertise, clearer development milestones, and stronger appeal to partners seeking targeted lipid‑lowering or cardiovascular programs over the medium term.
RNA-based Therapeutic ApproachAn RNA-based platform offers a mechanistic, modular approach to target specific genes in lipid metabolism. Platform technologies can create durable scientific differentiation, enable multiple candidate programs, and improve licensing prospects with larger pharma seeking novel modalities and precise mechanisms.
Debt-free Balance SheetZero reported debt reduces bankruptcy and interest burden risks, providing structural financial stability. For an R&D-centric biotech, lack of leverage lengthens optionality for partnership negotiations and grant funding, although it does not eliminate the need for external financing to sustain operations.
Bears Say
Persistent Negative Cash FlowSustained operating and free cash outflows indicate ongoing burn without internal cash generation. Over months, this materially increases reliance on external capital, risks asset depletion, and pressures management to raise funds or cut programs, undermining long‑term program continuity.
Volatile And Absent 2025 RevenueExtreme revenue volatility and a drop to zero in 2025 suggest irregular, non‑recurring receipts rather than durable product income. This weakens forecasting and reduces predictable cash inflows, complicating partnership valuations and making multi‑year planning and investment decisions harder.
Limited Internal Capacity And Funding DependenceA tiny workforce constrains in‑house development, increasing dependency on external partners or CROs for execution. Combined with a business model reliant on licensing and equity financing, this heightens execution and dilution risk, potentially slowing program advancement absent stable funding.
9RP FAQ
What was Lipigon Pharmaceuticals AB’s price range in the past 12 months?
Lipigon Pharmaceuticals AB lowest stock price was €0.00 and its highest was €0.02 in the past 12 months.
What is Lipigon Pharmaceuticals AB’s market cap?
Lipigon Pharmaceuticals AB’s market cap is €323.21K.
When is Lipigon Pharmaceuticals AB’s upcoming earnings report date?
Lipigon Pharmaceuticals AB’s upcoming earnings report date is May 20, 2026 which is in 39 days.
How were Lipigon Pharmaceuticals AB’s earnings last quarter?
Lipigon Pharmaceuticals AB released its earnings results on Feb 26, 2026. The company reported -€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.001.
Is Lipigon Pharmaceuticals AB overvalued?
According to Wall Street analysts Lipigon Pharmaceuticals AB’s price is currently Overvalued.
Does Lipigon Pharmaceuticals AB pay dividends?
Lipigon Pharmaceuticals AB does not currently pay dividends.
What is Lipigon Pharmaceuticals AB’s EPS estimate?
Lipigon Pharmaceuticals AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lipigon Pharmaceuticals AB have?
Lipigon Pharmaceuticals AB has 605,933,700 shares outstanding.
What happened to Lipigon Pharmaceuticals AB’s price movement after its last earnings report?
Lipigon Pharmaceuticals AB reported an EPS of -€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lipigon Pharmaceuticals AB?
Currently, no hedge funds are holding shares in DE:9RP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lipigon Pharmaceuticals AB
Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease and familial chylomicronemia syndrome; a gene therapy project for the lipodystrophy, a rare disease of altered fat distribution in the body; therapeutics for dyslipidemia, a general lipid disorder; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia, cardiovascular disease, and other metabolic diseases. The company was founded in 2010 and is based in Umeå, Sweden.